GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, announced it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update. This announcement is important for investors and stakeholders as it offers insights into the company's financial health and the progress of its key clinical programs, which address significant unmet medical needs.
The company's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. These trials evaluate its efficacy as a primary vaccine for immunocompromised patients, including those with hematologic cancers, as a booster for patients with chronic lymphocytic leukemia (CLL), and as a more robust, durable booster among healthy individuals previously vaccinated with mRNA vaccines. The outcomes of these trials could position GEO-CM04S1 as a critical alternative for populations that do not respond adequately to current COVID-19 vaccines, potentially addressing a gap in pandemic response strategies.
In oncology, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy. The company recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. If successful, Gedeptin® could offer a new treatment option for patients with limited alternatives, underlining the company's commitment to tackling challenging cancers. Additionally, GeoVax is developing a vaccine targeting Mpox and smallpox. Based on recent EMA regulatory guidance, the company anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. This accelerated pathway, if realized, could bring a much-needed vaccine to market faster, addressing public health concerns following the global Mpox outbreak.
Investors and interested parties can access the live conference call by registering in advance here. The live audio webcast will be available via the “Events & Presentations” section of the Company’s Investor Relations website at www.geovax.com/investors. An archive of the webcast will be available on the Company’s website approximately two hours after the conclusion of the call and will remain available for at least 90 days.
The financial results and corporate update will shed light on GeoVax's cash position, R&D expenditures, and operational milestones. With multiple clinical programs progressing, the company's ability to secure funding and achieve regulatory milestones is critical. The upcoming report may also provide clarity on the timeline for upcoming data readouts and regulatory submissions, which are pivotal for the company's valuation and future prospects. For more information about the current status of clinical trials and other updates, visit the company's website.
